VERISTRAT® Testing – A novel approach to NSCLC

October 27th, 2013

VeriStrat®, a serum based proteomic assay can help physicians identify patients who are likely to have good or poor outcomes after treatment with EGFR inhibitors and thereby can provide valuable insight into whether chemotherapy or targeted therapy with TARCEVA®, a EGFR-TKI, is appropriate for their patients with advanced NSCLC, in the second line setting. This information is especially important for patients without an EGFR mutation or for those, whose EGFR mutation status is unknown. In the PROSE trial, patients classified as VeriStrat-Poor have better survival with chemotherapy than TARCEVA®, whereas patients classified as VeriStrat-Good have similar survival with TARCEVA® and chemotherapy. This data was presented at the 2013 ASCO meeting.

PERJETA® combination Improves Response Rates

October 12th, 2013

The FDA on September 30, 2013 approved PERJETA® for use in combination with HERCEPTIN® (Trastuzumab) and TAXOTERE® (Docetaxel) for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer. The accelerated approval by the FDA was based solely on the improved pCR rate with the three drug combination with no demonstrable improvement in event-free survival or overall survival. A confirmatory phase III trial is underway, with results expected in 2016. One would hope that the complete response rates would translate into improved survival. Stay tuned.


October 6th, 2013

The recent approval by the FDA of ABRAXANE® in combination with GEMZAR® (Gemcitabine) for the first line treatment of patients with metastatic Adenocarcinoma of the Pancreas gives the Oncology Health Care Providers a much needed option to treat this group of patients. With a significant improvement in the Overall Survival, Progression Free Survival and Response Rates, ABRAXANE® combination will very likely replace the more toxic FOLFIRI regimen by virtue of its efficacy and tolerability.